These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1457 related articles for article (PubMed ID: 28752187)
1. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Wilson FR; Varu A; Mitra D; Cameron C; Iyer S Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187 [TBL] [Abstract][Full Text] [Related]
2. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037 [TBL] [Abstract][Full Text] [Related]
3. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis. Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747 [TBL] [Abstract][Full Text] [Related]
6. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278 [TBL] [Abstract][Full Text] [Related]
7. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis. Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880 [TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study. Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919 [TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials. Li H; Wu Y; Zou H; Koner S; Plichta JK; Tolaney SM; Zhang J; He YW; Wei Q; Tang L; Zhang H; Zhang B; Guo Y; Chen X; Li K; Lian L; Ma F; Luo S EBioMedicine; 2024 Jul; 105():105186. PubMed ID: 38861871 [TBL] [Abstract][Full Text] [Related]
10. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA; Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850 [TBL] [Abstract][Full Text] [Related]
11. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. Chirila C; Mitra D; Colosia A; Ling C; Odom D; Iyer S; Kaye JA Curr Med Res Opin; 2017 Aug; 33(8):1457-1466. PubMed ID: 28463012 [TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832 [TBL] [Abstract][Full Text] [Related]
13. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer. Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767 [TBL] [Abstract][Full Text] [Related]
14. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658 [TBL] [Abstract][Full Text] [Related]
15. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089 [TBL] [Abstract][Full Text] [Related]
16. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR Musolino A; Campone M; Neven P; Denduluri N; Barrios CH; Cortes J; Blackwell K; Soliman H; Kahan Z; Bonnefoi H; Squires M; Zhang Y; Deudon S; Shi MM; André F Breast Cancer Res; 2017 Feb; 19(1):18. PubMed ID: 28183331 [TBL] [Abstract][Full Text] [Related]
17. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China. Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648 [TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR Brufsky A; Mitra D; Davis KL; Nagar SP; McRoy L; Cotter MJ; Stearns V Clin Breast Cancer; 2019 Oct; 19(5):317-325.e4. PubMed ID: 31104984 [TBL] [Abstract][Full Text] [Related]
20. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]